Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.
We detected a significant excess risk for CHEK2*1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95% CI 1.5-28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.
Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam.
Annegien
A
Broeks
Lot
L
de Witte
Anke
A
Nooijen
Angelina
A
Huseinovic
Jan G M
JG
Klijn
Flora E
FE
van Leeuwen
Nicola S
NS
Russell
Laura J
LJ
van't Veer
D000328:Adult; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics*; D064447:Checkpoint Kinase 2; D005260:Female; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006579:Heterozygote; D006801:Humans; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*
D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases